Cargando…

Comparing access to orphan medicinal products in Europe

OBJECTIVES: The primary objective of this study was to compare the availability and access of orphan medicinal products (OMPs) in the devolved nations in the United Kingdom (UK), France, Germany, Italy and Spain. Availability is defined as the possibility to prescribe OMPs. Access refers to their fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zamora, Bernarda, Maignen, Francois, O’Neill, Phill, Mestre-Ferrandiz, Jorge, Garau, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499954/ https://www.ncbi.nlm.nih.gov/pubmed/31053154 http://dx.doi.org/10.1186/s13023-019-1078-5

Ejemplares similares

An analysis of orphan medicine expenditure in Europe: is it sustainable?
por: Mestre-Ferrandiz, Jorge, et al.
Publicado: (2019)

Does NICE influence the adoption and uptake of generics in the UK?
por: Serra-Sastre, Victoria, et al.
Publicado: (2020)

Access to Affordable Orphan Medicines in Europe: An EHA Position Paper
por: Merlini, Giampaolo, et al.
Publicado: (2020)

New pricing models for generic medicines to ensure long-term sustainable competition in Europe
por: Francois, Clement, et al.
Publicado: (2023)

Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
por: Brabers, Anne EM, et al.
Publicado: (2011)

Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
por: Pontes, Caridad, et al.
Publicado: (2018)

A comparative study of orphan drug prices in Europe
por: Young, Katherine Eve, et al.
Publicado: (2017)

Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
por: Schey, Carina, et al.
Publicado: (2011)

Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010–2019
por: Foltanova, Tatiana, et al.
Publicado: (2022)

Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years’ multi-stakeholder dialogue on improving access in Europe via MoCA
por: Cavaller-Bellaubi, Maria, et al.
Publicado: (2023)

The European challenges of funding orphan medicinal products
por: Szegedi, Márta, et al.
Publicado: (2018)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
por: Giannuzzi, Viviana, et al.
Publicado: (2017)

Regulatory Standards in Orphan Medicinal Product Designation in the EU
por: Tsigkos, Stelios, et al.
Publicado: (2021)

Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs
por: Giannuzzi, Viviana, et al.
Publicado: (2017)

Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation
por: Mulder, Jorn, et al.
Publicado: (2021)

Mechanism of coordinated access to orphan drugs
por: DeRidder, R, et al.
Publicado: (2012)

Patient access to orphan drugs in France
por: Bourdoncle, Marion, et al.
Publicado: (2019)

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
por: Morel, Thomas, et al.
Publicado: (2013)

A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
por: de Andrés-Nogales, Fernando, et al.
Publicado: (2021)

Access to innovative oncology medicines in Europe
por: Bergmann, L., et al.
Publicado: (2016)

Clinical evidence for orphan medicinal products-a cause for concern?
por: Picavet, Eline, et al.
Publicado: (2013)

Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
por: Pijeira Perez, Yankier, et al.
Publicado: (2023)

Making Sure That Orphan Incentives Tip the Right Way in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
por: Stolk, Pieter, et al.
Publicado: (2009)

Analysis of patient access to orphan drugs in Turkey
por: Koçkaya, Güvenç, et al.
Publicado: (2021)

Realising the broader value of vaccines in the UK
por: Brassel, Simon, et al.
Publicado: (2021)

Not one, but many: developing a multi-indication pricing model for medicines in Belgium
por: Maes, Ingrid, et al.
Publicado: (2023)

Principles for consistent value assessment and sustainable funding of orphan drugs in Europe
por: Gutierrez, Laura, et al.
Publicado: (2015)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Clinical pharmacology information in regulatory submissions and labeling: A comparative analysis of orphan and non‐orphan drugs approved by the FDA
por: Hsieh, Julie, et al.
Publicado: (2022)

Rare Diseases and Orphan Drugs Accessibility in Bosnia and Herzegovina
por: Guzvic, Vladmiri, et al.
Publicado: (2018)

Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
por: Picavet, Eline, et al.
Publicado: (2013)

Off-label use of orphan medicinal products: a Belgian qualitative study
por: Dooms, Marc, et al.
Publicado: (2016)

The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America
por: Arnold, Renée J.G., et al.
Publicado: (2015)

The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
por: Schuller, Y., et al.
Publicado: (2015)

Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Precision Medicines’ Impact on Orphan Drug Designation
por: Mueller, Christine M., et al.
Publicado: (2019)

Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
por: Hollak, Carla EM, et al.
Publicado: (2011)

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
por: Xoxi, Entela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h72h1jhefjfhcacjpqpqkjhn3j